Octanol

Octanol

SCHEMBL7215014

CCCCCCCCO.OC(F)(F)CF

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
ALDH1A1 P00352 2/20 0.62
HSD17B10 Q99714 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
TSHR P16473 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.57
FAAH O00519 7/20 0.40
CES1 P23141 6/20 0.40
CES2 O00748 3/20 0.40
CYP1A2 P05177 1/20 0.40
THRB P10828 1/20 0.38
LPAR1 Q92633 1/20 0.38
LPAR3 Q9UBY5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Heptane SCHEMBL7077193 0.90 TSHR (0.47) LMNAALDH1A1HSD17B10MEN1KMT2A
Hexane SCHEMBL28293459 0.87 FAAH (0.44) HSD17B10MEN1KMT2ATSHRSMN1; SMN2
Dodecanol SCHEMBL21384923 0.79 LMNA (0.77) LMNAALDH1A1HSD17B10MEN1KMT2A
Tridecan-1-Ol SCHEMBL27691275 0.79 LMNA (0.77) LMNAALDH1A1HSD17B10MEN1KMT2A
Cetyl Alcohol SCHEMBL27711529 0.79 LMNA (0.77) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL25421234 0.79 LMNA (1.00) LMNAALDH1A1HSD17B10MEN1KMT2A
Cetostearyl Alcohol SCHEMBL20515901 0.79 LMNA (1.00) LMNAALDH1A1HSD17B10MEN1KMT2A
Decane SCHEMBL11319155 0.79 LMNA (1.00) LMNAALDH1A1HSD17B10MEN1KMT2A
Myristyl Alcohol SCHEMBL21352636 0.79 LMNA (1.00) LMNAALDH1A1HSD17B10MEN1KMT2A
Docosanol SCHEMBL21218972 0.79 LMNA (1.00) LMNAALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613358-B2 Contacting an organic solvent with co-dissolved a biocompatible polymer and a hydrophobic ion pair complex of an amphiphilic material and pharmaceutical with a compressed antisolvent fluid ENDO PHARMACEUTICALS, INC. 2003-09-02 US disclosed
US-20020132007-A1 Sustainded-release composition including amorphous polymer UNIVERSITY TECHNOLOGY CORPORATION 2002-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132007-A1 Sustainded-release composition including amorphous polymer CHERP, ATP2A1, ATP2A3 LMNA 1490/4885ALDH1A1 4501/4885HSD17B10 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.